{"id":495068,"date":"2026-06-11T23:09:12","date_gmt":"2026-06-11T23:09:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/495068\/"},"modified":"2026-06-11T23:09:12","modified_gmt":"2026-06-11T23:09:12","slug":"74-real-world-study-characterizing-patient-characteristics-treatments-and-unmet-need-in-io-ineligible-patients-with-metastatic-triple-negative-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/495068\/","title":{"rendered":"74 Real-World Study Characterizing Patient Characteristics, Treatments, and Unmet Need in IO-Ineligible Patients With Metastatic Triple-Negative Breast Cancer"},"content":{"rendered":"<p> Background<\/p>\n<p class=\"\">Metastatic triple-negative breast cancer (mTNBC) is the most aggressive breast cancer subtype, with an estimated 15% five-year survival rate. Immunotherapy (IO) has demonstrated substantial anticancer effects, particularly in tumors overexpressing PD-L1. However, up to 70% of patients with previously untreated mTNBC may not be candidates for IO. Limited real-world (rw) evidence exists characterizing treatment patterns and clinical outcomes among these patients.<\/p>\n<p>Methods<\/p>\n<p class=\"\">This retrospective study, using electronic health record data from the ConcertAI Patient360\u2122 Breast dataset (01\/2021\u201301\/2025), included US patients \u2265 18 years with mTNBC who initiated first-line treatment in the metastatic setting. Patients were classified as IO-eligible and IO-ineligible: IO-eligible patients were PD-L1 positive (combined positive score \u2265 10, or other positive reported result) and had a disease-free interval (DFI) more than 12 months if treated with neoadjuvant\/adjuvant IO; while IO-ineligible patients were PD-L1 negative or had a DFI of 12 months or less. Kaplan-Meier analyses were used to estimate median real-world progression-free survival (PFS), real-world overall survival (OS), real-world time to discontinuation (TTD), and real-world time to next treatment (TTNT).<\/p>\n<p>Results<\/p>\n<p class=\"\">A total of 432 patients with mTNBC treated with first-line were identified, of whom 129 (29.9%) were IO-eligible and 303 (70.1%) were IO-ineligible. Overall, among IO-eligible and IO-ineligible, respectively, median age was 61 years; 69.0% and 61.7% were White; 79.1% and 74.0% received care in community setting; 12.5% and 5.4% had brain metastasis; and 70.6% and 73.6% had ECOG performance status 0-1, respectively. Treatments used in the first-line in patients who were IO-eligible and IO-ineligible were: 85.3% and 12.5% received IO-based regimens, 10.9% and 57.4% received chemotherapy-based regimens (without IO), and 3.9% and 30.0% received other regimens (without IO or chemotherapy), respectively. Overall, 13.2% of patients who were IO-eligible and 28.1% of IO-ineligible received first-line sacituzumab govitecan, either as monotherapy or in combination with chemotherapy, IO, or other agents. Only 43.4% and 39.0% of patients who were IO-eligible and IO-ineligible received treatment beyond first-line. Patients who were IO-eligible had longer median rwPFS, rwOS, rwTTD, and rwTTNT compared with those who were IO-ineligible (Table).<\/p>\n<p>Conclusions<\/p>\n<p class=\"\">In this real-world cohort of patients with mTNBC treated in the first-line setting, 70% were classified as IO-ineligible. While most patients who were IO-ineligible relied on conventional chemotherapy as first-line treatment, some were treated with IO or sacituzumab govitecan despite not being recommended by NCCN guidelines in the first-line setting for this population. Clinical outcomes were significantly worse for IO-ineligible patients compared with IO-eligible patients. Overall, limited treatment options and poor clinical outcomes, particularly in IO-ineligible patients, highlight significant unmet need in this population.<\/p>\n","protected":false},"excerpt":{"rendered":"Background Metastatic triple-negative breast cancer (mTNBC) is the most aggressive breast cancer subtype, with an estimated 15% five-year&hellip;\n","protected":false},"author":2,"featured_media":422481,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-495068","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/495068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=495068"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/495068\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/422481"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=495068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=495068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=495068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}